Q2 2026 Adjusted EBITDA 1 of $0.9M, the Company’s strongest quarterly performance since 2019 2 Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025 OPEX decreased 44% in Q2...
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
MediPharm Labs is pleased to announce the company will release its 2026 second quarter financial results before markets open on Thursday, August 13 2026....
TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in...
Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with...
Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant...
MediPharm Labs announces the results of matters voted on at its annual and special meeting of shareholders held today. ...
TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized...
Annual and Special Meeting to be held virtually on Wednesday, June 17, 2026 at 11:00 a.m. (Eastern Time). The Board of Directors recommends shareholders vote FOR all director nominees and resolutions,...
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA....